Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

Rhea-AI Summary

Clearside Biomedical, Inc. (NASDAQ:CLSD) will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time. The company's President and CEO, George Lasezkay, and Chief Medical Officer, Thomas A. Ciulla, will discuss Clearside's innovative SCS injection platform that targets therapies to the back of the eye. This platform aims to improve vision preservation and enhance treatment delivery for sight-threatening diseases. Live and archived webcasts will be available on their website.

ALPHARETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time, in New York, NY.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

What is the date and time of Clearside's Fireside Chat at the Stifel 2022 Healthcare Conference?

The Fireside Chat will take place on November 16, 2022, from 8:35 to 9:05 a.m. Eastern Time.

Who from Clearside Biomedical will participate in the Fireside Chat?

George Lasezkay, President and CEO, and Thomas A. Ciulla, Chief Medical Officer, will participate.

How can I access the webcast of Clearside Biomedical's Fireside Chat?

The webcast can be accessed live and archived under the Investors section on Clearside's website.

What technology does Clearside Biomedical use for therapy delivery?

Clearside utilizes the suprachoroidal space (SCS) injection platform for targeted therapy delivery to the back of the eye.

What is the main focus of Clearside Biomedical's product development?

Clearside focuses on developing therapies to preserve and improve vision in patients with sight-threatening eye diseases.